CA2122571A1 - Adhesion receptor antagonists - Google Patents
Adhesion receptor antagonistsInfo
- Publication number
- CA2122571A1 CA2122571A1 CA002122571A CA2122571A CA2122571A1 CA 2122571 A1 CA2122571 A1 CA 2122571A1 CA 002122571 A CA002122571 A CA 002122571A CA 2122571 A CA2122571 A CA 2122571A CA 2122571 A1 CA2122571 A1 CA 2122571A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor antagonists
- adhesion receptor
- fibrinogen
- formula
- mations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019997 adhesion receptor Human genes 0.000 title 1
- 108010013985 adhesion receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
Novel compounds of the formula I
(see formula I) in which R1, X and Y have the meanings given in Patent Claim 1, and their salts, inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for treating thromboses, stroke, cardiac infarction, inflam-mations, arteriosclerosis, osteoporosis and tumours.
(see formula I) in which R1, X and Y have the meanings given in Patent Claim 1, and their salts, inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for treating thromboses, stroke, cardiac infarction, inflam-mations, arteriosclerosis, osteoporosis and tumours.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4314378 | 1993-05-01 | ||
DEP4314378.4 | 1993-05-01 | ||
DE4405633A DE4405633A1 (en) | 1993-05-01 | 1994-02-22 | Adhesion receptor antagonists |
DEP4405633.8 | 1994-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2122571A1 true CA2122571A1 (en) | 1994-11-02 |
CA2122571C CA2122571C (en) | 2005-04-12 |
Family
ID=25925455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002122571A Expired - Fee Related CA2122571C (en) | 1993-05-01 | 1994-04-29 | Adhesion receptor antagonists |
Country Status (16)
Country | Link |
---|---|
US (1) | US5532255A (en) |
EP (1) | EP0623615B1 (en) |
JP (1) | JP3570744B2 (en) |
CN (1) | CN1052231C (en) |
AT (1) | ATE181735T1 (en) |
AU (1) | AU675698B2 (en) |
CA (1) | CA2122571C (en) |
CZ (1) | CZ285761B6 (en) |
DK (1) | DK0623615T3 (en) |
ES (1) | ES2134870T3 (en) |
GR (1) | GR3031271T3 (en) |
HU (1) | HU224549B1 (en) |
NO (1) | NO301419B1 (en) |
PL (1) | PL178131B1 (en) |
RU (1) | RU2145961C1 (en) |
SK (1) | SK281469B6 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627197A (en) * | 1995-02-15 | 1997-05-06 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Adhesion receptor antagonists |
WO2000029407A1 (en) * | 1998-11-18 | 2000-05-25 | Du Pont Pharmaceuticals Company | Isoxazoline fibrinogen receptor antagonists |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4332384A1 (en) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhesion receptor antagonists III |
DE4429461A1 (en) * | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhesion receptor antagonists |
DE19516483A1 (en) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhesion receptor antagonists |
DE19524765A1 (en) * | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds |
TR199801961T2 (en) * | 1996-03-30 | 1999-01-18 | Boehringer Mannheim Gmbh | New oxalidine derivatives, processes for their production, and pharmaceuticals containing these compounds. |
US5925635A (en) * | 1996-04-17 | 1999-07-20 | Dupont Pharmaceuticals Company | N-(amidinophenyl) cyclourea analogs as factor XA inhibitors |
US5877166A (en) * | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
DE19755268A1 (en) * | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidine derivatives |
ID30299A (en) | 1998-06-05 | 2001-11-22 | Astrazeneca Ab | OKSAZOLIDINON DERIVES, THE PROCESS OF MAKING IT AND THE PHARMACY COMPOSITION THAT CONTAINS IT |
BR9912638A (en) * | 1998-08-07 | 2001-05-02 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
DE19835950A1 (en) * | 1998-08-08 | 2000-02-10 | Merck Patent Gmbh | Piperazinone derivatives |
WO2000029406A2 (en) | 1998-11-18 | 2000-05-25 | Du Pont Pharmaceuticals Company | Novel isoxazoline fibrinogen receptor antagonists |
PL350291A1 (en) | 1998-12-23 | 2002-12-02 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
DE19958153A1 (en) * | 1999-12-03 | 2001-06-07 | Yamanouchi Pharma Co Ltd | Oxazolidinone derivatives |
DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
DE10129725A1 (en) | 2001-06-20 | 2003-01-02 | Bayer Ag | Combination therapy of substituted oxazolidinones |
DE10152460A1 (en) * | 2001-10-24 | 2003-05-08 | Bayer Ag | stents |
RU2314831C2 (en) | 2002-01-22 | 2008-01-20 | Фармация Энд Апджон Компани | Infection-proof medical devices |
US7141588B2 (en) * | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
DE10300111A1 (en) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide |
DE10322469A1 (en) * | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclic compounds |
JP4664634B2 (en) * | 2003-09-05 | 2011-04-06 | 富山化学工業株式会社 | Novel benzamidine derivatives or salts thereof |
DE10355461A1 (en) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases |
US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
JP2008512097A (en) * | 2004-09-07 | 2008-04-24 | アーケミックス コーポレイション | Aptamer medicinal chemistry |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
EP1789096A4 (en) | 2004-09-07 | 2009-07-08 | Archemix Corp | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
DE102004062475A1 (en) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Solid, orally administrable, modified release pharmaceutical dosage forms |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (en) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa |
US8188270B2 (en) | 2005-10-04 | 2012-05-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
DE102005047561A1 (en) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance |
DE102005047558A1 (en) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders |
DE102005048824A1 (en) * | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Treatment and prophylaxis of microangiopathies |
DE102006051625A1 (en) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Combination therapy of substituted oxazolidinones |
DE102007018662A1 (en) * | 2007-04-20 | 2008-10-23 | Bayer Healthcare Ag | Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension |
WO2008150495A2 (en) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Vwf aptamer formulations and methods for use |
DE102007028318A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Oxazolidinone for the treatment and prophylaxis of sepsis |
NZ586002A (en) * | 2007-12-11 | 2012-06-29 | Bayer Schering Pharma Ag | Oxazolidinones for the treatment and/or prophylaxis of heart failure |
EP2138178A1 (en) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma |
EP2140866A1 (en) | 2008-07-04 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract |
TWI759267B (en) | 2015-07-02 | 2022-04-01 | 美商地平線罕見醫學製藥有限責任公司 | Ado-resistant cysteamine analogs and uses thereof |
CN110573499B (en) | 2017-02-28 | 2023-04-21 | 莫菲克医疗股份有限公司 | Inhibitors of αvβ6 integrin |
CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
PE20211640A1 (en) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBITION OF INTEGRIN xvß6 |
WO2023172726A1 (en) * | 2022-03-10 | 2023-09-14 | Baruch S. Blumberg Institute | Novel diazepines that target yellow fever virus non-structural 4b (ns4b) protein and their method of use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1222708A (en) * | 1968-10-22 | 1971-02-17 | Delalande Sa | Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation |
US4886794A (en) * | 1987-05-07 | 1989-12-12 | A. H. Robins Company, Incorporated | 4-[(α,α-diaryl)-hydroxymethyl]-1-piperidinylalkyl-cyclic carbamate derivatives as allergic response inhibitors |
DE3723797A1 (en) * | 1987-07-18 | 1989-01-26 | Merck Patent Gmbh | OXAZOLIDINONE |
US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
DE4005371A1 (en) * | 1990-02-21 | 1991-08-22 | Merck Patent Gmbh | New N-(hetero)aryl-substd. 2-piperidino:ethyl oxazolidinone derivs. |
DE4017211A1 (en) * | 1990-05-29 | 1991-12-05 | Merck Patent Gmbh | OXAZOLIDINONE |
US5086055A (en) * | 1990-12-24 | 1992-02-04 | A. H. Robins Company, Incorporated | Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions |
DE4324393A1 (en) * | 1993-07-21 | 1995-01-26 | Merck Patent Gmbh | 4-aryloxy and 4-arylthiopiperidine derivatives |
-
1994
- 1994-04-19 AT AT94106049T patent/ATE181735T1/en not_active IP Right Cessation
- 1994-04-19 ES ES94106049T patent/ES2134870T3/en not_active Expired - Lifetime
- 1994-04-19 DK DK94106049T patent/DK0623615T3/en active
- 1994-04-19 EP EP94106049A patent/EP0623615B1/en not_active Expired - Lifetime
- 1994-04-21 AU AU60643/94A patent/AU675698B2/en not_active Ceased
- 1994-04-26 SK SK484-94A patent/SK281469B6/en unknown
- 1994-04-27 CZ CZ941019A patent/CZ285761B6/en not_active IP Right Cessation
- 1994-04-27 CN CN94105008A patent/CN1052231C/en not_active Expired - Fee Related
- 1994-04-28 PL PL94303242A patent/PL178131B1/en not_active IP Right Cessation
- 1994-04-28 JP JP09205894A patent/JP3570744B2/en not_active Expired - Fee Related
- 1994-04-29 RU RU94015184A patent/RU2145961C1/en not_active IP Right Cessation
- 1994-04-29 US US08/234,691 patent/US5532255A/en not_active Expired - Fee Related
- 1994-04-29 NO NO941592A patent/NO301419B1/en not_active IP Right Cessation
- 1994-04-29 CA CA002122571A patent/CA2122571C/en not_active Expired - Fee Related
- 1994-05-02 HU HU9401274A patent/HU224549B1/en not_active IP Right Cessation
-
1999
- 1999-09-22 GR GR990402369T patent/GR3031271T3/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627197A (en) * | 1995-02-15 | 1997-05-06 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Adhesion receptor antagonists |
WO2000029407A1 (en) * | 1998-11-18 | 2000-05-25 | Du Pont Pharmaceuticals Company | Isoxazoline fibrinogen receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
AU6064394A (en) | 1994-11-03 |
HU9401274D0 (en) | 1994-08-29 |
EP0623615B1 (en) | 1999-06-30 |
NO941592D0 (en) | 1994-04-29 |
JP3570744B2 (en) | 2004-09-29 |
RU2145961C1 (en) | 2000-02-27 |
CN1097421A (en) | 1995-01-18 |
US5532255A (en) | 1996-07-02 |
EP0623615A1 (en) | 1994-11-09 |
CZ285761B6 (en) | 1999-11-17 |
SK281469B6 (en) | 2001-04-09 |
ATE181735T1 (en) | 1999-07-15 |
HUT70541A (en) | 1995-10-30 |
PL178131B1 (en) | 2000-03-31 |
CA2122571C (en) | 2005-04-12 |
JPH072847A (en) | 1995-01-06 |
GR3031271T3 (en) | 1999-12-31 |
DK0623615T3 (en) | 1999-12-13 |
SK48494A3 (en) | 1995-02-08 |
HU224549B1 (en) | 2005-10-28 |
AU675698B2 (en) | 1997-02-13 |
NO941592L (en) | 1994-11-02 |
CZ101994A3 (en) | 1994-11-16 |
ES2134870T3 (en) | 1999-10-16 |
CN1052231C (en) | 2000-05-10 |
NO301419B1 (en) | 1997-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2122571A1 (en) | Adhesion receptor antagonists | |
GR3036838T3 (en) | Piperazinderivatives. | |
CA2175767A1 (en) | Adhesion receptor antagonists | |
DE58906377D1 (en) | Difluormethylverbindungen. | |
RU94015184A (en) | NEW CONNECTIONS AS ANTAGONISTS OF ADHESIVE RECEPTORS, METHOD OF THEIR PREPARATION, PHARMOCOMPOSITION ON THEIR BASIS AND METHOD OF IT | |
AU7305094A (en) | Adhesion receptor antagonists | |
AU632086B2 (en) | Carboxylic- and sulfonic acid amides | |
HU905605D0 (en) | Substituted imidazoles | |
CA2197793A1 (en) | New multimerizing agents | |
CA2096460A1 (en) | Dual action inhibitors | |
CA2093770A1 (en) | Aspartic acid derivatives, their preparation and use | |
GR3007512T3 (en) | ||
CA2040947A1 (en) | Platelet-aggregation inhibitors | |
CA2249410A1 (en) | Sigma-2 receptors as biomarkers of tumor cell proliferation | |
AU1257488A (en) | Layered divalent metal compositions | |
DE3766796D1 (en) | DI- OR POLYCYANATE COMPOUNDS AND SUBSTITUTED BICYCLO (2.2.1) HEPT-5-EN-2,3-DICARBONIC ACID IMIDES AND THEIR USE. | |
IE840831L (en) | 1,4-dihydropyridine derivatives | |
UA41280C2 (en) | OXAZOLIDINONES, THEIR SALTS, THE METHOD OF THEIR PREPARATION, THE PHARMACEUTICAL PREPARATION AND THE METHOD OF OBTAINING IT | |
AU7610194A (en) | Thiocarbamoyl compounds used as antimicrobial agents | |
IT8820182A0 (en) | BIOAVAILABLE IRON COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM. | |
MX9710389A (en) | Antagonists of the vitronectine receiver, their preparation and use of the same. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |